Elena N. Kliver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Elena N. Kliver has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Alexander G. Edemskiy
Meshalkin National Medical Research Center
5 shared publications - Denis S. Grankin
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской Федерации, Новосибирск
5 shared publications - Oksana Ya. Vasiltseva
Meshalkin National Medical Research Center
5 shared publications - Alexander Mikhailovich Chernyavskii
National Medical Research Center named after Academician E.N. Meshalkin; Novosibirsk State Medical University
4 shared publications О. Я. Васильцева
ФГБУ «Национальный медицинский исследовательский центр им. акад. Е.Н. Мешалкина» Минздрава России
3 shared publications- Alexander Romanov
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр имени академика Е.Н. Мешалкина» Министерства здравоохранения Российской Федерации
2 shared publications
Latest Publications
- Open Access
- 25 January 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (1) , 58-62
Therapies of chronic thromboembolic pulmonary hypertension: A review
The article addresses therapies for chronic thromboembolic pulmonary hypertension (CTEPH). The main challenges of patient management at various stages of diagnosis and treatment and the prevalence and pathogenesis of CTEPH are described. Immediate and long-term outcomes after treatment are evaluated. The study aims to present current therapies for CTEPH.
- 25 January 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (1) , 58-62
Open AccessTherapies of chronic thromboembolic pulmonary hypertension: A review
The article addresses therapies for chronic thromboembolic pulmonary hypertension (CTEPH). The main challenges of patient management at various stages of diagnosis and treatment and the prevalence and pathogenesis of CTEPH are described. Immediate and long-term outcomes after treatment are evaluated. The study aims to present current therapies for CTEPH.
- Open Access
- 1 November 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (4) , 297-304
Chronic thromboembolic pulmonary hypertension: epidemiology, diagnosis, treatment — current state of the problem
Chronic thromboembolic pulmonary hypertension is group IV of pulmonary hypertension, which develops with occlusive-stenotic lesions of the pulmonary artery after a pulmonary embolism. There are no clear data on the epidemiology of this disease. At the same time, it is obvious that it is much more widespread than is commonly believed. This is due to the nonspecific clinical picture and the lack of awareness of clinicians about this disease. On the one hand, the pathogenesis of CTEPH is well studied and in many respects similar to pulmonary arterial hypertension, on the other hand, it is not clear why blood clots do not dissolve in a certain percentage of patients. Diagnosis of chronic thromboembolic pulmonary hypertension is fairly well described and should be carried out according to a special algorithm. The treatment of choice is pulmonary endarterectomy. In inoperable patients and patients with residual pulmonary hypertension after surgery, it is possible to perform balloon angioplasty of the pulmonary artery and PAH-specific therapy. In our study, the safety and efficacy of a new method for the treatment of a residual form of chronic thromboembolic pulmonary hypertension, radiofrequency denervation of the pulmonary artery, has been proven. The pathogenetic basis of this technique is the desympathization of the pulmonary circulation by radiofrequency destruction of the autonomic ganglia of the bifurcation of the pulmonary artery and the interruption of the so-called pulmo-pulmonary reflex.
- 1 November 2023
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 78 (4) , 297-304
Open AccessChronic thromboembolic pulmonary hypertension: epidemiology, diagnosis, treatment — current state of the problem
Chronic thromboembolic pulmonary hypertension is group IV of pulmonary hypertension, which develops with occlusive-stenotic lesions of the pulmonary artery after a pulmonary embolism. There are no clear data on the epidemiology of this disease. At the same time, it is obvious that it is much more widespread than is commonly believed. This is due to the nonspecific clinical picture and the lack of awareness of clinicians about this disease. On the one hand, the pathogenesis of CTEPH is well studied and in many respects similar to pulmonary arterial hypertension, on the other hand, it is not clear why blood clots do not dissolve in a certain percentage of patients. Diagnosis of chronic thromboembolic pulmonary hypertension is fairly well described and should be carried out according to a special algorithm. The treatment of choice is pulmonary endarterectomy. In inoperable patients and patients with residual pulmonary hypertension after surgery, it is possible to perform balloon angioplasty of the pulmonary artery and PAH-specific therapy. In our study, the safety and efficacy of a new method for the treatment of a residual form of chronic thromboembolic pulmonary hypertension, radiofrequency denervation of the pulmonary artery, has been proven. The pathogenetic basis of this technique is the desympathization of the pulmonary circulation by radiofrequency destruction of the autonomic ganglia of the bifurcation of the pulmonary artery and the interruption of the so-called pulmo-pulmonary reflex.
- Open Access
- 22 September 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (7-8) , 361-367
Treatment of patients with chronic thromboembolic pulmonary hypertension
The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods. The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.
- 22 September 2023
- Published by Medical Informational Agency Publishers in Clinical Medicine (Russian Journal)
- Vol. 101 (7-8) , 361-367
Open AccessTreatment of patients with chronic thromboembolic pulmonary hypertension
The understanding of the tactics for managing patients with pulmonary hypertension (PH) of various etiologies is currently being developed. In August 2022, the European Society of Cardiology adopted new Guidelines for the management of patients with pulmonary hypertension. A separate cohort among them consists of patients with chronic thromboembolic pulmonary hypertension (CTEPH), classifi ed as Group 4 according to the WHO classifi cation. The possibilities of diagnosis, treatment methods, and their availability for this pathology have signifi cantly expanded over the past two decades. The aim of this study is to familiarize physicians with modern methods of treating CTEPH in order to timely refer patients to the most eff ective types of treatment currently available in expert centers in the Russian Federation. Materials and methods. The strategy for searching sources involved analyzing Medline (PubMed) and Scopus databases for the past 20 years using keywords such as diagnostic criteria for chronic thromboembolic pulmonary hypertension, treatment of chronic thromboembolic pulmonary hypertension. To search for additional materials on the topic, the lists of literature in relevant articles and reviews were analyzed.
- Open Access
- 7 October 2021
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 36 (3) , 154-160
Chronic thromboembolic pulmonary hypertension in an obese patient with type 2 diabetes mellitus
Metabolic disorders represent a serious medical and social problem and are risk factors for the development of thromboembolic complications. Disturbances of both carbohydrate and fat metabolism contribute to an increase in blood viscosity, creating prothrombotic conditions, which are not always objectively assessed even by specialists. In addition, multiple comorbid conditions usually significantly complicate the prognosis. The article presents a clinical case of recurrent thrombosis of the right atrium and the orifices of the superior and inferior vena cava in a 39-year-old patient with type 2 diabetes mellitus, obesity, arterial hypertension, and varicose vein disease.
- 7 October 2021
- Published by Cardiology Research Institute in Siberian Journal of Clinical and Experimental Medicine
- Vol. 36 (3) , 154-160
Open AccessChronic thromboembolic pulmonary hypertension in an obese patient with type 2 diabetes mellitus
Metabolic disorders represent a serious medical and social problem and are risk factors for the development of thromboembolic complications. Disturbances of both carbohydrate and fat metabolism contribute to an increase in blood viscosity, creating prothrombotic conditions, which are not always objectively assessed even by specialists. In addition, multiple comorbid conditions usually significantly complicate the prognosis. The article presents a clinical case of recurrent thrombosis of the right atrium and the orifices of the superior and inferior vena cava in a 39-year-old patient with type 2 diabetes mellitus, obesity, arterial hypertension, and varicose vein disease.
- Open Access
- 28 September 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (3) , 11-19
From pulmonary embolism to chronic thromboembolic pulmonary hypertension: risk factors
Chronic thromboembolic pulmonary hypertension is a long-term consequence of acute pulmonary embolism. Gradual obstruction of the pulmonary arteries and secondary changes in the pulmonary microcirculation over time cause progressive increases in pulmonary vascular resistance and pulmonary artery pressure that can result in severe right heart failure. This article provides an overview of pulmonary embolism and chronic thromboembolic pulmonary hypertension scientific literature and national guidelines. We focus on disease and recurrence risk factors and outline future directions of research to improve short- and long-term patient outcomes.Received 17 January 2021. Revised 1 March 2021. Accepted 19 April 2021.Funding: The study did not have sponsorship.Conflict of interest: The authors declare no conflicts of interests.Contribution of the authorsConception and study design: A.M. Chernyavskiy, A.G. Edemskiy, D.S. Grankin, E.N. KliverDrafting the article: O.Ya. VasiltsevaCritical revision of the article: E.N. KliverFinal approval of the version to be published: O.Ya. Vasiltseva, A.G. Edemskiy, D.S. Grankin, E.N. Kliver, A.M. Chernyavskiy
- 28 September 2021
- Published by Meshalkin National Medical Research Center in Patologiya krovoobrashcheniya i kardiokhirurgiya
- Vol. 25 (3) , 11-19
Open AccessFrom pulmonary embolism to chronic thromboembolic pulmonary hypertension: risk factors
Chronic thromboembolic pulmonary hypertension is a long-term consequence of acute pulmonary embolism. Gradual obstruction of the pulmonary arteries and secondary changes in the pulmonary microcirculation over time cause progressive increases in pulmonary vascular resistance and pulmonary artery pressure that can result in severe right heart failure. This article provides an overview of pulmonary embolism and chronic thromboembolic pulmonary hypertension scientific literature and national guidelines. We focus on disease and recurrence risk factors and outline future directions of research to improve short- and long-term patient outcomes.Received 17 January 2021. Revised 1 March 2021. Accepted 19 April 2021.Funding: The study did not have sponsorship.Conflict of interest: The authors declare no conflicts of interests.Contribution of the authorsConception and study design: A.M. Chernyavskiy, A.G. Edemskiy, D.S. Grankin, E.N. KliverDrafting the article: O.Ya. VasiltsevaCritical revision of the article: E.N. KliverFinal approval of the version to be published: O.Ya. Vasiltseva, A.G. Edemskiy, D.S. Grankin, E.N. Kliver, A.M. Chernyavskiy